Suppr超能文献

白内障术后大泡性角膜病变行角膜胶原交联术的疗效。

Outcomes of corneal collagen crosslinking in pseudophakic bullous keratopathy.

机构信息

Departments of Ophthalmology, *Cornea and Refractive Surgery Services, Dr Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India; †Centre for Eye Research Australia, University of Melbourne, Melbourne, Australia; and ‡Royal Victorian Eye and Ear Hospital, Melbourne, Australia.

出版信息

Cornea. 2014 Mar;33(3):243-6. doi: 10.1097/ICO.0000000000000004.

Abstract

PURPOSE

The aim was to evaluate the outcomes of corneal collagen crosslinking (CXL) in symptomatic pseudophakic bullous keratopathy (PBK).

METHODS

In a retrospective noncomparative, interventional case series, we reviewed the records of 50 eyes (50 patients) with symptomatic PBK who underwent CXL. Central corneal thickness (CCT), pain score, best corrected visual acuity (BCVA), and corneal transparency were recorded at baseline; at day 7, day 15; and 1, 3, and 6 months after the CXL.

RESULTS

The mean pain score decreased from 8.1 ± 0.6 at presentation to 2.1 ± 0.7 on day 7 (P = 0.0001). A subsequent regression was seen in pain scores over 6 months (5.3 ± 1.5). The mean CCT decreased from a preoperative value of 724.8 ± 78.4 to 694.9 ± 77.9 μm by the end of the first month (P = 0.0001). The CCT remained stable at subsequent follow-up. The BCVA improved from logarithm of the minimum angle of resolution (log MAR) 2.0 ± 0.5 preoperatively to log MAR 1.8 ± 0.5 by the end of the first month (P = 0.001). The subsequent follow-up showed a progressive deterioration in the BCVA to the preoperative levels at 6 months. Corneal bullae recurred in 44% (22 eyes) at 6 months after an initial disappearance. A significant improvement in the BCVA and a lack of recurrence of bullae were significantly associated with a thinner CCT on presentation.

CONCLUSIONS

CXL in symptomatic PBK temporarily improves pain without providing long-term improvement in the BCVA. Case selection is important with more effect seen in patients with a thinner CCT at presentation.

摘要

目的

评估角膜胶原交联 (CXL) 治疗症状性白内障术后大泡性角膜病变 (PBK) 的疗效。

方法

在一项回顾性非对照、干预性病例系列研究中,我们回顾了 50 只眼(50 例)接受 CXL 治疗的症状性 PBK 患者的记录。在基线时、术后第 7 天、第 15 天以及术后第 1、3 和 6 个月,记录中央角膜厚度 (CCT)、疼痛评分、最佳矫正视力 (BCVA) 和角膜透明度。

结果

疼痛评分从就诊时的 8.1 ± 0.6 分降至第 7 天的 2.1 ± 0.7 分(P = 0.0001),之后疼痛评分在 6 个月内逐渐下降(5.3 ± 1.5)。CCT 从术前的 724.8 ± 78.4μm 降至术后第 1 个月的 694.9 ± 77.9μm(P = 0.0001),之后在随访中保持稳定。BCVA 从术前的 logMAR 2.0 ± 0.5 提高至术后第 1 个月的 logMAR 1.8 ± 0.5(P = 0.001),之后随访中 BCVA 逐渐恢复至术前水平。术后第 6 个月,初始消失后有 44%(22 只眼)再次出现角膜大疱。BCVA 的显著改善和大疱的无复发与术前 CCT 更薄显著相关。

结论

CXL 治疗症状性 PBK 可暂时缓解疼痛,但不能长期改善 BCVA。病例选择很重要,术前 CCT 较薄的患者效果更明显。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验